Inadvertent Germline Transmission of AAV2 Vector: Findings in a Rabbit Model Correlate with Those in a Human Clinical Trial
Authors:
- Joerg SchuettrumpfJSJoerg Schuettrumpf
- Jian-Hua LiuJLJian-Hua Liu
- Linda B CoutoLCLinda B Couto
- Kathakaly AddyaKAKathakaly Addya
- Debra G B LeonardDLDebra G B Leonard
- Zhu ZhenZZZhu Zhen
- Jürg SommerJSJürg Sommer
- Jürg SummerJSJürg Summer
- Valder R ArrudaVAValder R Arruda
Open Access
- 1 June 2006
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 13 (6) , 1064-1073
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal modelBlood, 2005
- Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapyBlood, 2005
- No evidence for germ‐line transmission following prenatal and early postnatal AAV‐mediated gene deliveryThe Journal of Gene Medicine, 2005
- Infectious Titer Assay for Adeno-Associated Virus Vectors with Sensitivity Sufficient to Detect Single Infectious EventsHuman Gene Therapy, 2004
- Direct Exposure of Mouse Spermatozoa to Very High Concentrations of a Serotype-2 Adeno-Associated Virus Gene Therapy Vector Fails to Lead to Germ Cell TransductionHuman Gene Therapy, 2004
- Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaquesBlood, 2002
- A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with AntrostomiesHuman Gene Therapy, 2002
- Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in MalesMolecular Therapy, 2001
- A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung DiseaseHuman Gene Therapy, 2001
- Clinical Protocol: Phase I Clinical Trial Utilizing Gene Therapy for Limb Girdle Muscular Dystrophy: alpha -, beta -, gamma -, or delta -Sarcoglycan Gene Delivered with Intramuscular Instillations of Adeno-Associated VectorsHuman Gene Therapy, 2000